Promising Diabetes Medication Demonstrates Anti-Aging Benefits in Patients with Type 2 Diabetes
A recent study reveals that henagliflozin, a common diabetes medication, may also promote cellular aging reduction by increasing telomere length in patients with type 2 diabetes, offering potential anti-aging benefits.
Recent research highlights the anti-aging potential of henagliflozin, a widely used medication for managing type 2 diabetes. A multicenter clinical trial published in Cell Reports Medicine examined whether this drug could influence aging biomarkers, particularly telomere length, which serves as a marker for cellular aging.
The study involved 142 adults aged 35 to 70 years with diagnosed type 2 diabetes. Participants were randomly assigned to receive either 10 mg of henagliflozin daily or a placebo over a period of 26 weeks. Along with monitoring glucose levels, researchers assessed changes in telomere length in blood leukocytes and levels of insulin-like growth factor-1 (IGF-1), both of which are associated with aging and metabolic health.
Findings revealed that those taking henagliflozin experienced a significant increase in telomere length compared to the placebo group. Specifically, 90.5% of the patients on the drug showed telomere extension, versus 65.6% in the placebo group. This suggests that henagliflozin may have an inherent anti-aging effect, alongside its primary function of lowering blood sugar.
The study also observed improvements in glucose metabolism and immune function. It’s noteworthy that both groups underwent identical lifestyle interventions, indicating that the observed effects are likely due to the drug’s pharmacological properties rather than external factors.
SGLT2 inhibitors like henagliflozin work by reducing glucose reabsorption in the kidneys, which not only helps control blood sugar but also promotes weight loss and mimics caloric restriction — a well-documented strategy for slowing biological aging. Despite promising preclinical data, there has been limited clinical evidence confirming these anti-aging benefits.
This research opens exciting avenues for integrating treatment of metabolic diseases with anti-aging strategies. However, further studies with larger populations are necessary to fully understand the potential of henagliflozin to combat aging and delay age-related diseases.
The implications are particularly significant given the rising global prevalence of type 2 diabetes. Combining metabolic disease management with anti-aging interventions could enhance quality of life and lifespan, making this an important development in medical research.
Source: https://medicalxpress.com/news/2025-09-popular-diabetes-drug-anti-aging.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Enhanced Access to Social Support Programs Boosts Treatment for Women with Drug Use Disorders
A new study reveals that combining Medicaid with social support services significantly increases treatment access for women with drug and opioid use disorders. Expanded social safety net programs can help address treatment gaps and barriers faced by women with substance use issues.
FDA Approves New Sublingual Nonopioid Treatment for Fibromyalgia
The FDA has approved Tonmya, a novel sublingual, nonopioid medication, for adults with fibromyalgia, marking a significant advancement in pain management options for this chronic condition.
Pocket Ultrasound Technology Shortens Hospital Stays for Patients with Breathing Difficulties, Study Reveals
A groundbreaking study shows that pocket ultrasound devices significantly cut hospital stays and costs for patients with breathing difficulties, offering a faster and more accurate diagnostic tool for clinicians.
Projected Doubling of Kidney Cancer Cases by 2050 Highlights Growing Health Concern
A study predicts that kidney cancer cases worldwide will double by 2050, driven by lifestyle factors such as obesity and smoking. Early detection and prevention are crucial to addressing this rising health challenge.